TY - JOUR
T1 - Vascular brachytherapy for hemodialysis vascular access dysfunction
T2 - Exploring an unmet clinical need
AU - Roy-Chaudhury, Prabir
AU - Duncan, Heather
AU - Barrett, William
AU - Elson, Howard
AU - Narayana, Ashwath
AU - Foley, Jeri
AU - Misra, Sanjay
AU - Lynch, Pia Mikkelsen
AU - Zuckerman, Darryl
PY - 2003/1
Y1 - 2003/1
N2 - Hemodialysis vascular access dysfunction is a major cause of morbidity and hospitalization in the hemodialysis population (230,000 patients in the United States) at a cost of well over 1 billion dollars per annum. Venous stenosis and thrombosis (due to venous neointimal hyperplasia), is the most common cause of hemodialysis vascular access dysfunction. At the clinical level this manifests in the form of a 50%, one-year primary patency for new grafts, and a dismal 40% 3-month survival for thrombosed grafts. However, despite the magnitude of the clinical problem, there are currently no effective therapies for this condition. We and others have previously demonstrated that venous neointimal hyperplasia in polytetrafluoroethylene (PTFE) dialysis grafts is composed of smooth muscle cells/myofibroblasts, a perigraft macrophage layer and microvessels within the venous neointima. Interestingly, there is strong experimental evidence which demonstrates that radiation therapy blocks the proliferation and activation of all these cell types. In addition, endovascular radiation therapy has already been successfully used to prevent restenosis following coronary angioplasty. The BRAVO trial is a randomized, multi-center, double-blind clinical trial of endovascular radiation in PTFE dialysis grafts, sponsored by the Novoste Corporation. This trial is particularly significant as it is the first large multi-center study that is focused on testing a novel local intervention in the specific setting of dialysis access dysfunction. The rationale behind this study, and its design and the logistics involved, will also be described in this review.
AB - Hemodialysis vascular access dysfunction is a major cause of morbidity and hospitalization in the hemodialysis population (230,000 patients in the United States) at a cost of well over 1 billion dollars per annum. Venous stenosis and thrombosis (due to venous neointimal hyperplasia), is the most common cause of hemodialysis vascular access dysfunction. At the clinical level this manifests in the form of a 50%, one-year primary patency for new grafts, and a dismal 40% 3-month survival for thrombosed grafts. However, despite the magnitude of the clinical problem, there are currently no effective therapies for this condition. We and others have previously demonstrated that venous neointimal hyperplasia in polytetrafluoroethylene (PTFE) dialysis grafts is composed of smooth muscle cells/myofibroblasts, a perigraft macrophage layer and microvessels within the venous neointima. Interestingly, there is strong experimental evidence which demonstrates that radiation therapy blocks the proliferation and activation of all these cell types. In addition, endovascular radiation therapy has already been successfully used to prevent restenosis following coronary angioplasty. The BRAVO trial is a randomized, multi-center, double-blind clinical trial of endovascular radiation in PTFE dialysis grafts, sponsored by the Novoste Corporation. This trial is particularly significant as it is the first large multi-center study that is focused on testing a novel local intervention in the specific setting of dialysis access dysfunction. The rationale behind this study, and its design and the logistics involved, will also be described in this review.
KW - Endovascular radiation therapy
KW - Hemodialysis vascular access dysfunction
KW - Smooth muscle cell proliferation
KW - Venous neointimal hyperplasia
KW - Venous stenosis
UR - http://www.scopus.com/inward/record.url?scp=0037837615&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037837615&partnerID=8YFLogxK
M3 - Review article
C2 - 12668839
AN - SCOPUS:0037837615
SN - 1042-3931
VL - 15
SP - 25A-30A
JO - Journal of Invasive Cardiology
JF - Journal of Invasive Cardiology
IS - SUPPL. A
ER -